Latest | F'cast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | -59.3% | n/a |
ROCE | n/a |
Latest | F'cast | |
---|---|---|
P/E | n/a | n/a |
PEG | n/a | n/a |
Pr/Revenue | 2.5 | n/a |
Pr/Book | n/a |
Latest | F'cast | |
---|---|---|
Revenue | -16.2% | n/a |
PBT | n/a | n/a |
EPS | n/a | n/a |
DPS | n/a | n/a |
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
30-Jun-19 | 73.72 | 4.29 | 0.55p | 25.5 | n/a | n/a | n/a | 0.0% |
30-Jun-20 | 78.20 | 8.07 | 1.11p | 12.6 | 0.1 | +102% | n/a | 0.0% |
30-Jun-21 | 84.33 | 3.66 | 0.45p | 55.6 | n/a | -60% | n/a | 0.0% |
30-Jun-22 | 72.77 | (12.66) | (2.14)p | n/a | n/a | n/a | n/a | 0.0% |
30-Jun-23 | 60.95 | (49.83) | (7.61)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Further detail from G306 Phase III field trial | 07-May-2024 | 07:00 | RNS |
Director Resignation | 03-Apr-2024 | 07:00 | RNS |
Interim Results for six months ended 31 Dec 2023 | 27-Mar-2024 | 07:00 | RNS |
Allergy drug firm hit by trials setback | 12-Jul-2007 | The Independent |
Need to Know: Global Business Briefing | 25-Mar-2006 | Times |
No deals were found in the last 28 days.
Currency | UK Pounds |
Share Price | 3.25p |
Change Today | -0.100p |
% Change | -2.99 % |
52 Week High | 6.25 |
52 Week Low | 0.88 |
Volume | 591,351 |
Shares Issued | 4,766.44m |
Market Cap | £154.91m |
RiskGrade | 268 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
16:26 | 34,261 @ 3.21p |
15:58 | 29,969 @ 3.31p |
14:00 | 5,000 @ 3.25p |
14:00 | 5,000 @ 3.25p |
13:04 | 49,000 @ 3.40p |
You are here: research